Patents by Inventor Vega Masignani

Vega Masignani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modified meningococcal fHbp polypeptides
    Patent number: 11939357
    Abstract: The inventors have identified residues within variant 2 and variant 3 of meningococcal fHpb which can be modified to enhance their properties.
    Type: Grant
    Filed: June 14, 2021
    Date of Patent: March 26, 2024
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Matthew Bottomley, Vega Masignani
  • MENINGOCOCCUS VACCINES
    Publication number: 20230414736
    Abstract: Meningococcal vaccines can be improved by including multiple alleles or variants of fHbp, in order to provide broader coverage of the diversity which is known for this protein, and/or by reducing the quantity of an OMV component in each dose.
    Type: Application
    Filed: June 6, 2023
    Publication date: December 28, 2023
    Inventors: Alessia BIOLCHI, Brunella BRUNELLI, Marzia GIULIANI, Vega MASIGNANI
  • Meningococcus vaccines
    Patent number: 11707513
    Abstract: Meningococcal vaccines can be improved by including multiple alleles or variants of fHbp, in order to provide broader coverage of the diversity which is known for this protein, and/or by reducing the quantity of an OMV component in each dose.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: July 25, 2023
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Alessia Biolchi, Brunella Brunelli, Marzia Monica Giuliani, Vega Masignani
  • MODIFIED MENINGOCOCCAL FHBP POLYPEPTIDES
    Publication number: 20220002355
    Abstract: The inventors have identified residues within variant 2 and variant 3 of meningococcal fHpb which can be modified to enhance their properties.
    Type: Application
    Filed: June 14, 2021
    Publication date: January 6, 2022
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Matthew BOTTOMLEY, Vega MASIGNANI
  • Modified meningococcal fHbp polypeptides
    Patent number: 11066450
    Abstract: The inventors have identified residues within variant 2 and variant 3 of meningococcal fHbp which can be modified to enhance their properties.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: July 20, 2021
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Matthew Bottomley, Vega Masignani
  • PSEUDOMONAS ANTIGENS AND ANTIGEN COMBINATIONS
    Publication number: 20200360504
    Abstract: An effective Pseudomonas aeruginosa vaccine may require one or several antigenic components, and so various antigens of P. aeruginosa are identified for use in immunisation. These polypeptides may optionally be used in combination with other nosocomial antigens.
    Type: Application
    Filed: August 7, 2020
    Publication date: November 19, 2020
    Applicants: GlaxoSmithKline Biologicals SA, Ospedale San Raffaele Srl
    Inventors: Vega MASIGNANI, Maria SCARSELLI, Roberto PETRACCA, Irene BIANCONI, Alessandra BRAGONZI, Beatriz ALCALA' FRANCO
  • Nucleic acids and proteins from streptococcus groups A and B
    Patent number: 10428121
    Abstract: The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: October 1, 2019
    Assignees: Novartis AG, J. Craig Venter Institute, Inc.
    Inventors: John Telford, Vega Masignani, Maria Scarselli, Guido Grandi, Herve Tettelin, Claire Fraser
  • proteins and nucleic acids
    Patent number: 10226524
    Abstract: The invention provides proteins from Staphylococcus aureus including amino acid sequences and the corresponding nucleotide sequences. The proteins are useful for vaccines, immunogenic compositions, diagnostics, enzymatic studies and also as targets for antibiotics.
    Type: Grant
    Filed: August 17, 2017
    Date of Patent: March 12, 2019
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Vega Masignani, Marirosa Mora, Maria Scarselli
  • PROTEINS AND NUCLEIC ACIDS FROM MENINGITIS/SEPSIS-ASSOCIATED ESCHERICHIA COLI
    Publication number: 20180298064
    Abstract: Disclosed herein are various open reading frames from a strain of E. coli responsible for neonatal meningitis (MNEC), and a subset of these that is of particular interest for preparing compositions for immunising against MNEC infections.
    Type: Application
    Filed: June 26, 2018
    Publication date: October 18, 2018
    Applicants: GlaxoSmithKline Biologicals SA, J. Craig Venter Institute, Inc.
    Inventors: Vega MASIGNANI, Danilo Gomes MORIEL, Francesco BERLANDA SCORZA, Nathalie NORAIS, Maria Rita FONTANA, Mariagrazia PIZZA, Laura SERINO, Hervé TETTELIN
  • PSEUDOMONAS ANTIGENS AND ANTIGEN COMBINATIONS
    Publication number: 20180256701
    Abstract: An effective Pseudomonas aeruginosa vaccine may require one or several antigenic components, and so various antigens of P. aeruginosa are identified for use in immunisation. These polypeptides may optionally be used in combination with other nosocomial antigens.
    Type: Application
    Filed: May 11, 2018
    Publication date: September 13, 2018
    Applicants: GlaxoSmithKline Biologicals SA, Ospedale San Raffaele Srl
    Inventors: Vega MASIGNANI, Maria SCARSELLI, Roberto PETRACCA, Irene BIANCONI, Alessandra BRAGONZI, Beatriz ALCALA' FRANCO
  • MENINGOCOCCUS VACCINES
    Publication number: 20180214531
    Abstract: Meningococcal vaccines can be improved by including multiple alleles or variants of fHbp, in order to provide broader coverage of the diversity which is known for this protein, and/or by reducing the quantity of an OMV component in each dose.
    Type: Application
    Filed: July 16, 2015
    Publication date: August 2, 2018
    Inventors: Alessia Biolchi, Brunella Brunelli, Marzia Monica Giuliani, Vega Masignani
  • Proteins and nucleic acids from meningitis/sepsis-associated
    Patent number: 10035826
    Abstract: Disclosed herein are various open reading frames from a strain of E. coli responsible for neonatal meningitis (MNEC), and a subset of these that is of particular interest for preparing compositions for immunizing against MNEC infections.
    Type: Grant
    Filed: May 9, 2016
    Date of Patent: July 31, 2018
    Assignees: GlaxoSmithKline Biologicals SA, J. Craig Venture Institute, Inc.
    Inventors: Vega Masignani, Danilo Gomes Moriel, Francesco Berlanda Scorza, Nathalie Norais, Maria Rita Fontana, Mariagrazia Pizza, Laura Serino, Herve Tettelin
  • antigens and antigen combinations
    Patent number: 9987344
    Abstract: An effective Pseudomonas aeruginosa vaccine may require one or several antigenic components, and so various antigens of P. aeruginosa are identified for use in immunization. These polypeptides may optionally be used in combination with other nosocomial antigens.
    Type: Grant
    Filed: November 27, 2013
    Date of Patent: June 5, 2018
    Assignees: GlaxoSmithKline Biologicals SA, Ospedale San Raffaele S.R.L.
    Inventors: Vega Masignani, Maria Scarselli, Roberto Petracca, Irene Bianconi, Alessandra Bragonzi, Beatriz Alcala′ Franco
  • NUCLEIC ACIDS AND PROTEINS FROM STREPTOCOCCUS GROUPS A AND B
    Publication number: 20180094033
    Abstract: The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics.
    Type: Application
    Filed: November 7, 2017
    Publication date: April 5, 2018
    Inventors: John TELFORD, Vega MASIGNANI, Maria SCARSELLI, Guido GRANDI, Herve TETTELIN, Claire FRASER
  • Nucleic acids and proteins from groups A and B
    Patent number: 9840538
    Abstract: The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: December 12, 2017
    Assignees: Novartis AG, J. Craig Venter Institute, Inc.
    Inventors: John Telford, Vega Masignani, Maria Scarselli, Guido Grandi, Herve Tettelin, Claire Fraser
  • STAPHYLOCOCCUS AUREUS PROTEINS AND NUCLEIC ACIDS
    Publication number: 20170348407
    Abstract: The invention provides proteins from Staphylococcus aureus including amino acid sequences and the corresponding nucleotide sequences. The proteins are useful for vaccines, immunogenic compositions, diagnostics, enzymatic studies and also as targets for antibiotics.
    Type: Application
    Filed: August 17, 2017
    Publication date: December 7, 2017
    Applicant: GLAXOSMITHKLINE BIOLOGICALS, SA
    Inventors: Vega MASIGNANI, Marirosa MORA, Maria SCARSELLI
  • proteins and nucleic acids
    Patent number: 9764020
    Abstract: The invention provides proteins from Staphylococcus aureus including amino acid sequences and the corresponding nucleotide sequences. The proteins are useful for vaccines, immunogenic compositions, diagnostics, enzymatic studies and also as targets for antibiotics.
    Type: Grant
    Filed: February 22, 2016
    Date of Patent: September 19, 2017
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Vega Masignani, Marirosa Mora, Maria Scarselli
  • Nucleic acids and proteins from streptococcus groups A and B
    Patent number: 9738693
    Abstract: The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: August 22, 2017
    Assignees: Novartis AG, J. Craig Venter Institute, Inc.
    Inventors: John Telford, Vega Masignani, Maria Scarselli, Guido Grandi, Herve Tettelin, Claire Fraser
  • MODIFIED MENINGOCOCCAL FHBP POLYPEPTIDES
    Publication number: 20170226161
    Abstract: The inventors have identified residues within variant 2 and variant 3 of meningococcal fHbp which can be modified to enhance their properties.
    Type: Application
    Filed: July 16, 2015
    Publication date: August 10, 2017
    Applicant: GLAXOSMITHKLINE BIOLOGICALS, SA
    Inventors: Matthew Bottomley, Vega Masignani
  • HETEROLOGOUS EXPRESSION OF NEISSERIAL PROTEINS
    Publication number: 20170080077
    Abstract: Alternative and improved approaches to the heterologous expression of the proteins of Neisseria meningitidis and Neisseria gonorrhoeae are disclosed. These approaches typically affect the level of expression, the ease of purification, the cellular localization, and/or the immunological properties of the expressed protein.
    Type: Application
    Filed: December 2, 2016
    Publication date: March 23, 2017
    Applicant: GlaxoSmithKline Biologicals SA
    Inventors: Maria ARICÒ, Maurizio COMANDUCCI, Cesira GALEOTTI, Vega MASIGNANI, Marzia Monica GIULIANI, Mariagrazia PIZZA